• 1577 Citations
  • 17 h-Index
1982 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Maria Ornella Nicoletto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Ovarian Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Carboplatin Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Platinum Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2018

  • 1577 Citations
  • 17 h-Index
  • 70 Article
20 Citations (Scopus)

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Friedlander, M., Gebski, V., Gibbs, E., Davies, L., Bloomfield, R., Hilpert, F., Wenzel, L. B., Eek, D., Rodrigues, M., Clamp, A., Penson, R. T., Provencher, D., Korach, J., Huzarski, T., Vidal, L., Salutari, V., Scott, C., Nicoletto, M. O., Tamura, K., Espinoza, D. & 2 others, Joly, F. & Pujade-Lauraine, E., Aug 1 2018, In : The Lancet Oncology. 19, 8, p. 1126-1134 9 p.

Research output: Contribution to journalArticle

Maintenance Chemotherapy
Platinum
Ovarian Neoplasms
Placebos
Quality of Life
30 Citations (Scopus)

Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells

Pagotto, A., Pilotto, G., Mazzoldi, E. L., Nicoletto, M. O., Frezzini, S., Pastò, A. & Amadori, A., Jul 20 2017, In : Cell Death and Disease. 8, 7, p. e2943

Research output: Contribution to journalArticle

Neoplastic Stem Cells
Autophagy
Ovarian Neoplasms
Neoplasms
Recurrence
12 Citations (Scopus)

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Daniele, G., Lorusso, D., Scambia, G., Cecere, S. C., Nicoletto, M. O., Breda, E., Colombo, N., Artioli, G., Cannella, L., Lo Re, G., Raspagliesi, F., Maltese, G., Salutari, V., Ferrandina, G., Greggi, S., Baldoni, A., Bergamini, A., Piccirillo, M. C., Tognon, G., Floriani, I. & 3 others, Signoriello, S., Perrone, F. & Pignata, S., Feb 1 2017, In : Gynecologic Oncology. 144, 2, p. 256-259 4 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Drug Therapy
Surgical Wound Dehiscence
Bevacizumab
12 Citations (Scopus)

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the

Daniele, G., Lorusso, D., Scambia, G., Cecere, S. C., Nicoletto, M. O., Breda, E., Colombo, N., Artioli, G., Cannella, L., Lo Re, G., Raspagliesi, F., Maltese, G., Salutari, V., Ferrandina, G., Greggi, S., Baldoni, A., Bergamini, A., Piccirillo, M. C., Tognon, G., Floriani, I. & 3 others, Signoriello, S., Perrone, F. & Pignata, S., Feb 1 2017, In : Gynecologic Oncology. 144, 2, p. 256-259 4 p.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Daniele, G., Lorusso, D., Scambia, G., Cecere, S. C., Nicoletto, M. O., Breda, E., Colombo, N., Artioli, G., Cannella, L., Lo Re, G., Raspagliesi, F., Maltese, G., Salutari, V., Ferrandina, G., Greggi, S., Baldoni, A., Bergamini, A., Piccirillo, M. C., Tognon, G., Floriani, I. & 3 others, Signoriello, S., Perrone, F. & Pignata, S., 2017, In : Gynecologic Oncology. 144, 2, p. 256-259 4 p.

Research output: Contribution to journalArticle